Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Obesity 3Breast Neoplasms 3Prostatic Neoplasms 2Overweight 2Melanoma 2Skin Neoplasms 1Metabolic Syndrome 1Kidney Neoplasms 1Inflammation 1Glioma 1Glioblastoma 1Dyslipidemias 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 12Early Intervention, Educational 7Methods 6Practice Guidelines as Topic 5Neoadjuvant Therapy 5Immunohistochemistry 5Counseling 5Chemotherapy, Adjuvant 5Anastrozole 5Standard of Care 4Specimen Handling 4Radiotherapy 4Psychiatric Rehabilitation 4Mastectomy, Segmental 4Mass Spectrometry 4Letrozole 4Educational Status 4Behavior Therapy 4Gene Expression Profiling 3Biopsy 3exemestane 2Telemedicine 2Taxes 2Surveys and Questionnaires 2Soybean Proteins 2Simvastatin 2Sentinel Lymph Node Biopsy 2Radiosurgery 2Radiation Dose Hypofractionation 2Radiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Carcinoma In Situ × Naltrexone × Clear all
NCT02137252 2021-11-16

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡